What Ангельмин Treats: Main Uses and Benefits

Ангельмин is generally used for short-term symptomatic assistance in clinical settings that involve acute or disruptive symptom patterns. This medicine is commonly used when supportive symptom management is appropriate, assisting with conditions characterized by periods of heightened symptoms and functional strain. Its use is relevant for symptomatic assistance during acute episodes associated with conditions like schizophrenia or bipolar I or II disorder. It is applied in scenarios where additional management of discomfort is required.

Key Benefits and Therapeutic Domains

Ангельмин helps address symptom clusters that may become intense or disruptive, contributing to improving day-to-day comfort during symptomatic periods. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations. The medication is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed.

“It provides support that may help ease the overall symptom load during episodes of heightened discomfort.”

Quick Fact: Support for Acute Symptom Manifestations The medicine is often used when symptoms intensify, offering supportive relief when symptoms interfere with routine activities.

Official Eligibility Profile for Ангельмин (Albendazole)

Official regulatory documents define strict criteria for who can and cannot use this medicine, based primarily on reproductive status, age, and pre-existing medical conditions.

Interactions with other Medicines and Products

The most critical known interaction for Ангельмин involves medicines belonging to the class of Monoamine Oxidase Inhibitors (MAOIs). The concurrent use of Ангельмин with an MAOI is contraindicated (strictly prohibited) due to the significant and potentially life-threatening risk of a hypertensive crisis (a dangerous, rapid rise in blood pressure).

This restriction extends to medications that are either non-selective MAOIs or selective MAO-A inhibitors. The severe adverse reaction is a pharmacodynamic effect resulting from the combined impact of the medicines on neurotransmitter levels.

To prevent this hazardous interaction, a washout period is mandatory. Individuals must not use Ангельмин if they have taken an MAOI within the preceding 14 days. This 14-day interval allows the MAOI to be sufficiently cleared from the body, reducing the risk of a dangerous reaction. Always inform your healthcare provider about all prescription drugs, non-prescription drugs, and supplements you are taking before starting treatment with Ангельмин.

Ангельмин is identified as Imeglimin, a tetrahydrotriazine-containing compound that exerts a dual mechanism of action on pancreatic beta cells and peripheral tissues, namely the liver and skeletal muscle. At the cellular level, the molecule modulates mitochondrial function by interacting with components of the electron transport chain. Specifically, it has been observed to partially inhibit Complex I and restore activity of Complex III in the respiratory chain, resulting in an immediate reduction of cellular reactive oxygen species (ROS) formation and subsequent decrease in oxidative stress. This improved mitochondrial bioenergetics leads to an amplified, glucose-dependent increase in ATP generation within the pancreatic beta cell. The consequent rise in the ATP/ADP ratio and subsequent intracellular signaling cascade leads to enhanced glucose-stimulated insulin secretion (GSIS). Simultaneously, this modulation of mitochondrial function in key tissues contributes to an overall enhancement of insulin action in the liver and skeletal muscle, which includes an inhibitory effect on hepatic glucose output and improvements in tissue-specific insulin signaling.

The use of Ангельмин (Albendazole) is defined by established administration protocols. The medicine is for oral administration and is taken with food, specifically a fatty meal, as this condition increases the systemic absorption of the active ingredient. This condition is a requirement for utilization as outlined in standard prescribing guidelines.

Dosing is determined by the specific parasitic infection and the patient's body weight. For adults weighing 60 kg or more, the standard dose is 400 mg per dose, administered twice daily (BID). For patients weighing less than 60 kg or for pediatric use, the dose is calculated based on 15 mg per kilogram of body weight daily, divided into two doses, with a maximum total daily amount of 800 mg.

The duration of treatment is specifically defined and condition-dependent. For complex cystic infections, such as Hydatid Disease, the drug is administered in 28-day treatment cycles, followed by a 14-day period without medication, a regimen typically repeated for a total of three cycles. In contrast, the course for Neurocysticercosis is administered continuously for 8 to 30 days. To facilitate intake, the tablets may be crushed or chewed and swallowed with water if there is difficulty swallowing them whole.

Research evidence / Overview of Studies for Ангельмин (Albendazole)

Evidence for Systemic and Tissue-Invasive Infections

This section will summarize the research base exploring the clinical evaluation of this medicine for complex conditions like neurocysticercosis and cystic hydatid disease. It will outline the types of controlled clinical trials and observational studies that evaluated outcomes related to changes in cyst status (resolution and size) and patient seizure frequency.

The research primarily involves Randomized Controlled Trials (RCTs) and systematic reviews. Findings describe patterns where studies monitored changes in cyst status and the frequency of generalized seizure events in the evaluated groups, often comparing them to groups that received no specific therapy. Studies monitoring cyst status reported that the total disappearance of cysts was observed in some cohorts over the study period. What remains uncertain is the long-term status for all patients, as follow-up durations were limited in some early evidence.

Evidence for Intestinal and Soil-Transmitted Infections

This area will summarize the extensive research, primarily randomized controlled trials (RCTs) and meta-analyses, that examined this medicine against common parasites like Ascaris and hookworm. The focus will be on the study designs used to measure cure rates and the percentage change in parasite egg counts.

Studies monitored outcomes using two standardized metrics: the Cure Rate (CR) and the Egg Reduction Rate (ERR). For Ascaris and hookworm infections, the data show patterns related to high CR and ERR measurements observed in the studies. Research also examined outcomes for Trichuris trichiura (whipworm), but findings were mixed: studies reported patterns of lower CR measurements against this specific parasite species, although ERR measurements remained high in many settings. The measured outcome was associated with the specific parasite species studied and the treatment regimen administered. The evidence for Trichuris suggests lower consistency in measured cure rates, and research is ongoing to further explore management approaches for this parasite.

Long-Term Outcomes and Follow-up Data

Longitudinal observational studies have monitored cohorts for both neurocysticercosis and hydatid disease for up to several years. For patients with neurocysticercosis, research highlights that a substantial proportion of people continue reporting neurological symptoms, such as headaches and seizures, years after the initial diagnosis and intervention, regardless of the treatment group. There is limited information for long-term outcomes showing sustained cyst-free status for all patients. Long-term effects are not fully established, and some studies observing responses over defined time intervals have described patterns of relapse or recurrence of cysts, especially in hydatid disease.

Key Studies & References

1. Short course of albendazole therapy for neurocysticercosis: A prospective randomized trial comparing...
2. Guideline: Preventive Chemotherapy to Control Soil-Transmitted Helminth Infections in At-Risk Population Groups (WHO)
3. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials
4. Present drugs and future perspectives in treating soil-transmitted helminthiasis (Discussing T. trichiura efficacy gaps)

Common questions about Ангельмин (FAQ)

Q: Can Ангельмин be used in patients with a history of liver problems?

According to the official product information, patients with pre-existing or active liver impairment are at an increased risk for toxicity. Regulatory documents note that monitoring of liver enzymes (blood tests) is necessary during the treatment course.

Q: Do official documents mention any food or diet restrictions while taking Ангельмин?

Official documents specify that administration with a fatty meal is necessary to promote proper absorption and effectiveness. Some regulatory sources also caution against significantly altering the intake of grapefruit or grapefruit juice, as this may be associated with higher drug concentrations in the body.

Q: How does Ангельмин affect laboratory blood tests or screening procedures?

Official labeling notes that monitoring of blood counts and liver enzymes is necessary. This precaution is advised because treatment may be associated with changes, such as elevations in liver enzymes or, rarely, a reduction in blood counts (known as bone marrow suppression).

Q: Is Ангельмин safe for use in children under the age of 12, according to official documents?

Official documents restrict the use of this medicine in children under two years of age. For older children, the drug is approved for use in systemic infections, and official protocols often include the 6-to-12 age range for common parasitic indications.

Q: Are there any specific safety warnings for older patients (65+) using Ангельмин?

Regulatory documents do not typically require a specific dose adjustment based on age alone for geriatric patients. However, caution may be necessary for older individuals who have co-existing organ impairment, particularly liver dysfunction.

Q: Do official sources provide information on the use of Ангельмин during pregnancy or breastfeeding?

The medicine is classified as contraindicated in pregnancy due to a documented risk of fetal harm. Regarding breastfeeding, official analysis indicates that the drug and its active metabolite are minimally transferred into breastmilk.

Q: Is there information on the potential for Ангельмин to cause allergic reactions?

Official documentation notes that hypersensitivity (an allergic reaction) to the drug or its pharmacological class is a contraindication to use. While rare, serious allergic reactions, including severe skin reactions like Stevens-Johnson Syndrome, have been reported in the official adverse event profile.

Q: Why do some people report feeling no effect from taking Ангельмин?

The drug's absorption into the body is highly conditional, as described in official prescribing information. The need for administration with a fatty meal is based on the fact that this condition significantly increases the concentration of the active ingredient needed for the medicine to work effectively.

Q: Can I take Ангельмин if I have a history of mental health issues or seizures?

For patients being treated for neurocysticercosis (a specific infection), there is a documented risk of developing neurological symptoms. Official warnings note that seizures or increased pressure inside the skull may occur shortly after starting therapy, leading to a need for close medical observation.

Q: Can a patient use over-the-counter pain relievers (like ibuprofen) while taking Ангельмин?

Official drug interaction checkers generally indicate that there is no known interaction between this medicine and common over-the-counter pain relievers, such as ibuprofen.

Q: What happens if I accidentally take a slightly higher dose than prescribed (non-emergency)?

Official information indicates that the known risks of the medicine, such as bone marrow suppression, may be amplified with higher doses. Any ingestion of a dose above that prescribed can increase the potential for adverse effects.

Q: Are there any restrictions on driving or operating machinery while on this medication?

The official adverse reaction list includes central nervous system effects such as dizziness, headache, and vertigo. These effects may impact a patient's ability to safely operate machinery or drive a vehicle.

Q: Can individuals with a history of kidney issues use Ангельмин?

Since the clearance of the active drug is minimally handled by the kidneys, official product information indicates that no dosage adjustment is typically required for individuals with renal impairment.

Q: Can a patient safely consume a moderate amount of alcohol while taking Ангельмин?

The drug carries a documented risk of liver damage. Because this risk may be increased by concurrent alcohol consumption, the use of alcohol during treatment is discouraged.

Q: Why do official documents caution against using Ангельмин with grapefruit or grapefruit juice?

Official documentation mentions that grapefruit juice can increase the absorption of the medicine. This could lead to a higher concentration of the drug in the blood, potentially increasing the risk of experiencing side effects.

The storage of Ангельмин (Albendazole) must align strictly with regulatory requirements to preserve product stability.

Storage Conditions

The medicine is classified for Controlled Room Temperature storage, specifically 20 C to 25 C (68 F to 77 F), with a maximum limit not exceeding 30 C. The product must be kept from freezing and protected away from heat, moisture, and direct light. For safety, the product must be stored in a closed container and kept out of the reach of children.

Disposal Instructions

Official disposal guidance requires that any unused or expired medicine must be discarded in accordance with local requirements. Patients must consult local authorities or a healthcare professional to ensure proper pharmaceutical waste management.